For Immediate Release

Chicago, IL – April 28, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Dynavax Technologies Corp. (DVAX),Skyworks Solutions, Inc. (SWKS), Wilmington Trust Corp. (WL), Micromet Inc. (MITI) and Embraer (ERJ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday’s Analyst Blog:

Dynavax Surge Not Warranted

In early morning trading, Dynavax Technologies Corp. (NASDAQ: DVAX) shares shot up dramatically (36%). However, we don’t see a clear reason for that.

The surge may be related to two pieces of news: phase III Heplisav data and the swine flu breakout.

The first piece of news is about its phase III candidate Heplivsav. This morning, the company announced the oral presentation of additional phase III clinical data for Heplisav hepatitis B vaccine in a session for late-breaking abstracts at the 44th Annual Meeting of the European Association for the Study of Liver Disease (EASL) in Copenhagen, Denmark.

Skyworks Gives Stellar Guidance

Despite ahead-of-expectations Q2 results and better-than-expected Q3 guidance, shares of Skyworks Solutions, Inc. (SWKS, Buy) are lower in trading today. The company posted Q2 revenue of $173 million with non-GAAP EPS of $0.12, compared to our and consensus estimate of $168 million in revenue and proforma EPS of $0.10.

The company’s expansion in high-margin, high-end smart phones and push-to-talk applications along with energy management and smart grid technologies were the main drivers of growth during the quarter. The company also captured key design wins at Huawei and ZTE for 3G and 4G base station solutions, which is expected to drive growth further in Q3.

WL Beats but Gets Downgraded

Wilmington Trust Corp. (WL) reported its 1Q09 financial results this morning. 1Q09 net income came in at $21.8 million or $0.26 per diluted share, compared to a net loss of $68.5 million $1.02 per diluted share in the prior quarter and net income of $41.4 million or $0.61 per diluted share in the prior-year quarter.

On an operating basis (excluding after-tax securities gains and write-downs), net income for 1Q09 was $17.4 million or $0.19 per diluted share, compared to a net loss of $6.1 million or $0.09 per diluted share for 4Q08. Operating earnings were substantially ahead of estimates, mainly due to a lower-than-expected provision expense which more than offset the decline in net interest income and non-interest income.

MITI Updates on Drug Development

On Friday April 24, 2009, Micromet Inc. (MITI) held a briefing for investors and financial analysts in New York to provide an update on the company’s drug development pipeline.

A key highlight of the presentation was the announcement that a rapid path to market has been identified in acute lymphoblastic leukemia (ALL) for the company’s lead drug candidate BiTE antibody blinatumomab (MT103) with a registration trial planned for 2010. This was in addition to a dose escalation study which is currently underway of blinatumomab for non Hodgkin’s lymphoma, with final results expected to be reported at the American Society of Hematology meeting in December.

Brazilian Gov’t Helps Embraer

Last week, Brazil announced an increase in credit lines to trade finance with Argentina from its existing US$120 million to US$1.5 billion.

It sounds like a huge step toward the integration of Latin American economies, but it is not. Argentina is really facing a credit shortage since the unilateral debt restructuring in 2001 and, for sure, this difficult situation has not improved lately. However, this new credit line is not supposed to solve this problem.

The original amount of US$120 million was outdated and the from a total of US$1.5 billion of the new facility, US$700 million will be just to finance Aerolineas Argentinas in the acquisition of 20 MB 190 jets from Embraer (ERJ). Embraer has been facing a difficult period in the past few months as the Global crisis reduces the demand from airline companies worldwide.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Zacks Investment Research

Last 5 posts by Zacks Market Commentaries

• CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
• Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
• Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
• Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
• GameStop Meets Expectations - Analyst Blog - November 20th, 2009